SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland
1 references·1 citing·9 second hop
Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland (2001)Economic Evaluation of Celecoxib, a New C…Costs, effects and C/E‐ratios alongside a clinical trial (1994)Costs, effects and C/E‐ratios…A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example (2009)A Comparison of Cost Effectiv…Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)National Institute for Clinical Excellence and its value judgments (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)The true cost of pharmacological disease prevention (2011)A Guide to Simulation (1983)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Handling Uncertainty in Cost-Effectiveness Models (2000)Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions (2004)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)
this work references cited by second hop

References

  • 1994Costs, effects and C/E‐ratios alongside a clinical trial963 cited

Cited by

  • 2009A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example59 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work